Novel IGSF8 Plus Keytruda Evaluated in Phase 1 Trial for Solid Tumors
Two immune checkpoint inhibitors are being evaluated together in a phase 1 trial for certain patients with advanced solid tumors.
Source: curetoday.com
Page 25 - Solid Tumors News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Solid Tumors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Solid Tumors Today - Breaking & Trending Today
Overview of Tumor agnostic Treatment: Considerations for NGS Testing in Solid Tumors
Experts discuss the importance of NGS testing for identifying actionable alterations like RET fusions in solid tumors and when to consider testing.
Source: onclive.com
RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024
LOS ALTOS - RenovoRx, Inc. , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun Bagai,...
Source: marketscreener.com
Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that preclinical data on multiple novel bispecific antibodies as well as antibody-drug-conjugates (ADCs) from its oncology pipeline are presented at the American Association for Cancer Research (AACR) Annual Meetin
Source: yahoo.com
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
VANCOUVER, British Columbia, April 08, 2024 -- Zymeworks Inc. , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the...
Source: marketscreener.com